A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly
as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris,
a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma,
a therapeutic agent of peripheral circulation disorder, a prophylactic agent of
immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an
anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune
disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive
tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy
and a brain function improving drug. In addition, the Rho kinase inhibitor is provided
as a reagent and a diagnostic.
